CoImmune specializes in the development of immuno-oncology therapies using its proprietary platform technologies. Their autologous RNA-loaded dendritic cell technology targets unique tumor antigens in solid tumors, while their allogeneic CAR-CIK technology shows strong efficacy with reduced toxicity in clinical trials for acute lymphoblastic leukemia. Founded in 2019, CoImmune is based in Durham, North Carolina, and focuses on developing cell-based therapeutics for unmet medical needs, including cancer and autoimmune diseases. They aim to utilize biological components from each patient to activate an immune response specific to their disease, offering personalized treatment options for patients.